Pharmacological treatment of cognitive deficits in schizophrenic patients: the effects of central cholinergic augmentation on cognitive deficits and psychopathology.

Trial Profile

Pharmacological treatment of cognitive deficits in schizophrenic patients: the effects of central cholinergic augmentation on cognitive deficits and psychopathology.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2011

At a glance

  • Drugs Donepezil; Ziprasidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Sep 2011 Planned end date (Jan 2005) added as reported by ClinicalTrials.gov.
    • 19 Sep 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top